People in the study are assigned by chance to receive either inclisiran or placebo, and neither the participants nor the study team knows which one is given. The study follows participants over time while they receive the injections and are checked regularly for major heart-related problems such as myocardial infarction (heart attack), ischemic stroke (stroke caused by a blocked blood vessel), death from heart disease, or urgent procedures to open blocked heart arteries. The main purpose of the study is to find out whether inclisiran lowers the risk of these serious events better than placebo.

The purpose of the study is to see if ziltivekimab works better than placebo in reducing the risk of serious heart-related problems in people who have both cardiovascular disease and kidney disease along with signs of inflammation in their body. The main focus is on preventing major cardiovascular events, which include death from heart-related causes, non-fatal heart attack, and non-fatal stroke. A heart attack occurs when blood flow to part of the heart muscle is blocked, while a stroke happens when blood flow to part of the brain is interrupted.

During the study, participants will receive either ziltivekimab or placebo through regular injections while continuing their standard medical treatment. The study will track various health outcomes over time, including heart attacks, strokes, heart-related deaths, hospital admissions for heart problems, and changes in kidney function. Researchers will also monitor changes in inflammation markers in the blood, heart function measurements, and overall health status. The study will measure how the kidneys are working by looking at blood test results that show the filtering ability of the kidneys and the amount of protein in the urine, which can indicate kidney damage.

Participants in the study will be assigned to receive either muvalaplin, which is taken as an oral tablet, or a placebo. This is a randomized study, meaning the treatment assigned is determined by chance, and it is double-blind, so neither the participants nor the researchers know which treatment is being given during the trial. The study will monitor how the medication affects the risk of experiencing major heart events over time.

Participants will be assigned to receive either olpasiran or a placebo through a subcutaneous injection, which means the medication is delivered into the fatty tissue just under the skin. During the study, researchers will monitor for various health events such as ischemic stroke, which is a blockage of blood flow to the brain, and cardiovascular death. The study will also track changes in the levels of lipoprotein (a) in the blood over time to see how the treatment affects this substance.

During the study, participants will be monitored over a period of time to see how the medication affects the occurrence of major health events. These events include myocardial infarction, commonly known as a heart attack, stroke, or being hospitalized due to heart failure. The study also looks at coronary revascularization, which is a procedure used to improve blood flow to the heart, and any deaths caused by any reason.

The treatment involves taking MK-1403 in the form of an oral capsule, which is a pill taken by mouth. During the study, researchers will monitor pharmacokinetics, which refers to how the body absorbs, distributes, processes, and eliminates a medication over time. This process helps determine how much of the substance stays in the blood and how long it remains active in the system.

The purpose of this study is to find out if olpasiran can reduce the amount of a specific type of plaque in the heart arteries called non-calcified plaque, which is softer plaque that has not yet hardened with calcium deposits. The study will also look at whether the treatment is safe and well tolerated by participants. The amount of plaque will be measured using a special imaging test called coronary computed tomography angiography, which creates detailed pictures of the heart arteries.

During the study, participants will receive either olpasiran or placebo through an injection under the skin using a pre-filled syringe. The study will last for approximately 72 weeks, during which time imaging scans will be performed to compare the amount of plaque in the arteries at the beginning and end of the treatment period. The study will also measure changes in other types of plaque, including low attenuation plaque, which is a type of softer plaque, total plaque volume, and calcified plaque, which is hardened plaque containing calcium deposits.

The purpose of the study is to find out how well different doses of DII235 work in lowering lipoprotein(a) levels compared to placebo, and to check if the treatment is safe and well-tolerated. The study will also look at whether DII235 can reduce lipoprotein(a) levels to specific target amounts over time. People taking part in this study will have either existing heart and blood vessel disease, which means they have had problems like heart attacks, procedures to open blocked arteries, narrowing of arteries in the heart, brain, or legs, or they have Type 2 diabetes mellitus, which is a condition where the body does not properly control blood sugar levels.

During the study, participants will receive injections under the skin over a period of 18 months. The study doctors will measure lipoprotein(a) levels in the blood at different time points to see how much they change from the beginning of the study. Measurements will be taken at various times including around day 60, day 180, day 240, and day 360. The study will also track any unwanted effects, check blood test results, and monitor vital signs like blood pressure and heart rate to make sure the treatment is safe. Participants will need to continue taking their regular medications for heart health and cholesterol as prescribed by their doctor throughout the study.

The purpose of this research is to evaluate how safe the medication is and how well patients tolerate it when used for a longer period. The medication is given as a subcutaneous injection (under the skin) using a pre-filled syringe. This is an open-label extension study, which means all participants will receive the actual medication, and it continues treatment for patients who completed an earlier study called Lp(a)HORIZON.

During the study, participants will receive regular doses of pelacarsen for up to 36 months. The maximum daily dose is 80 milligrams. The study will monitor participants’ health through regular check-ups and blood tests to ensure their safety while taking the medication. Researchers will track various health measurements and any side effects that may occur during the treatment period.

The study tests whether olpasiran is more effective than a placebo in reducing the risk of serious heart-related events. These events include coronary heart disease death, myocardial infarction (heart attack), and emergency procedures to restore blood flow to the heart. The medication is being studied specifically in people who have high levels of lipoprotein(a) in their blood and are considered at risk for heart problems.

During the study, participants will receive either olpasiran or a placebo while continuing their usual heart medications. The study will track any heart-related events that occur and measure how the treatment affects the amount of lipoprotein(a) in the blood. This research is part of a larger program called OCEAN(a)-PreEvent, which aims to better understand how to prevent first-time heart problems in people with high lipoprotein(a) levels.

The purpose of this research is to determine if AZD0780 can reduce the risk of serious cardiovascular events such as heart attacks, strokes, and problems with blood flow to the legs in people with cardiovascular disease. The medication will be tested in addition to patients’ regular cholesterol-lowering treatments.

During the study, participants will receive either AZD0780 or a placebo for up to 54 months. The study team will monitor participants for any cardiovascular events, including heart-related death, heart attacks, strokes, severe leg circulation problems, and emergency procedures to restore blood flow. Throughout the study, participants will continue their usual heart medications, including their regular cholesterol-lowering treatments.

The medication is given as a solution for injection under the skin (subcutaneous use). During the study, participants will receive either maridebart cafraglutide or placebo. The study will track important heart-related events that may occur, such as heart attacks, strokes, and the need for heart procedures.

The research team will monitor participants’ health throughout the study, focusing particularly on heart and blood vessel-related events. The study will look at whether the medication can help prevent serious heart problems and improve survival rates in people who have both cardiovascular disease and weight issues.

The purpose of this research is to determine if pelacarsen, when used together with inclisiran, can effectively reduce levels of Lp(a) in the blood. During the study, participants will receive either pelacarsen or placebo as an injection under the skin, while all participants will receive inclisiran. Both medications will be given through pre-filled syringes with safety devices.

The study will last for approximately 12 months. Throughout this time, participants will need to continue taking their regular heart medications. Doctors will monitor participants’ health through regular check-ups and blood tests to ensure safety and measure how well the treatment is working.

The purpose of the study is to understand how blood platelets, which help with clotting, behave in people with Type 1 Diabetes compared to healthy individuals. The study will also look at the presence of plaques, which are fatty deposits in the arteries, and how they relate to blood clotting in people with diabetes. Participants will be observed over a period of time to see if aspirin affects these factors and if it can predict changes in artery health or the risk of heart disease.

Participants will be monitored for changes in their blood clotting and artery health, with some taking aspirin for at least seven days. The study will also investigate the relationship between blood clotting and inflammation, which is the body’s response to injury or infection, in people with Type 1 Diabetes. The trial aims to provide insights into how these factors might predict future health outcomes related to heart and blood vessel health.

Participants in the study will be divided into two groups. One group will receive atorvastatin, a cholesterol-lowering medication, while the other group will receive a placebo. The study will last for about a year, and during this time, researchers will monitor changes in the participants’ arteries to see if atorvastatin can slow down the progression of atherosclerosis compared to the placebo. The main focus will be on the arteries in the chest area, specifically the descending thoracic aorta.

Throughout the study, researchers will also look at other factors, such as changes in the heart’s arteries and overall heart health, as well as any side effects experienced by participants. The goal is to gather information on whether atorvastatin can be beneficial for patients undergoing ICI therapy by potentially reducing the risk of heart-related issues associated with atherosclerosis.

Participants in the study will receive colchicine, which is taken orally, to see if it can help manage the inflammation in their coronary arteries, which are the blood vessels that supply the heart. The study will also involve the use of a special type of scan called a PET-scan to measure changes in the blood vessels over a period of 12 weeks. This scan helps to visualize how much of a certain substance, called 68Gallium-DOTATATE, is taken up by the blood vessels, which indicates the level of inflammation.

The trial will also monitor other health indicators, such as the condition of the carotid arteries and aorta, which are major blood vessels, as well as the overall health of the spleen and bone marrow. Additionally, the study will track any major heart-related events, like heart attacks or strokes, and any side effects related to the immune therapy. The goal is to understand if colchicine can provide a protective effect for patients undergoing cancer treatment, potentially improving their overall health outcomes.

The purpose of the study is to determine if pelacarsen can reduce the risk of major heart-related events, such as heart attacks, strokes, and the need for urgent heart procedures, in people who already have cardiovascular disease. Participants in the study will receive either the pelacarsen treatment or a placebo. The study will monitor participants over a period to see how the treatment affects their health and the occurrence of these major events.

Throughout the study, participants will receive regular injections and will be closely monitored by healthcare professionals. The study will help researchers understand if lowering lipoprotein (a) with pelacarsen can provide significant benefits for people with cardiovascular disease. The results could lead to new treatment options for managing heart health in the future.

The purpose of the study is to evaluate how the combination of Obicetrapib and Ezetimibe affects the volume of non-calcified plaques in the coronary arteries over a period of 18 months. Participants will undergo a special type of imaging called Coronary CT Angiography to measure changes in their coronary plaque characteristics. This imaging method provides detailed pictures of the heart’s blood vessels, helping researchers understand how the treatment impacts plaque buildup.

Participants in the study will be randomly assigned to receive either the combination treatment or a placebo. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual treatment or the placebo. This approach helps ensure that the results are unbiased. The study will last for 18 months, during which participants will have regular check-ups and imaging tests to monitor their heart health and the effects of the treatment.

The treatment being studied, INZ-701, is a type of medication that is given as an injection under the skin. It is a specially designed protein that aims to help manage these conditions. The study will follow participants who have already received INZ-701 in a previous clinical study to see how they respond to the treatment over a longer period.

Participants in this study will receive regular injections of INZ-701 and will be monitored for any side effects or changes in their health. The study will look at how often and how severe any side effects are, as well as any changes in laboratory tests. This information will help researchers understand the long-term safety of INZ-701 for people with these rare conditions.

The purpose of the study is to examine how Repatha affects a specific heart condition known as coronary microvascular dysfunction, which involves problems with the small blood vessels in the heart. The study will compare the effects of a single dose of Repatha with no treatment in patients who have been diagnosed with atherosclerotic cardiovascular disease and require a procedure called coronarography, which is an imaging test to look at the heart’s blood vessels.

Participants in the study will receive either the medication or no treatment and will be monitored over a period of four weeks. The study aims to provide insights into how Repatha might help improve the function of the heart’s small blood vessels in patients with this type of heart disease. The results could potentially lead to better treatment options for individuals with atherosclerotic cardiovascular disease.

The study will involve taking either the treatment or a placebo, which looks like the treatment but does not contain the active medicine. DFV890 is taken as a film-coated tablet, while MAS825 is given as a concentrate for infusion, which means it is administered through a needle under the skin. Participants will be randomly assigned to different groups to receive either the treatment or the placebo. The study will last for a period of up to 84 days, during which participants will have regular check-ups to monitor their health and the effects of the treatment.

Throughout the study, participants will have their blood tested to measure levels of certain inflammatory markers, which are substances in the blood that can indicate inflammation. The study will also monitor for any side effects or changes in health, including vital signs like blood pressure and heart rate, as well as conducting tests like electrocardiograms (ECGs) to check heart function. The goal is to understand how well the treatments work and how safe they are for people with coronary heart disease and CHIP.

The purpose of the study is to evaluate how safe and tolerable INZ-701 is for infants with these deficiencies. The study will involve giving the treatment as an injection under the skin. Participants will be closely monitored to see how their bodies respond to the treatment, including any side effects they might experience. The study will also look at how the treatment moves through the body and how it affects certain biological markers related to the conditions.

Throughout the study, various health checks will be conducted, such as monitoring vital signs, weight, and conducting laboratory tests. These tests will help researchers understand the impact of INZ-701 on the participants’ health. The study aims to gather important information that could lead to better treatments for infants with ENPP1 Deficiency or ABCC6 Deficiency in the future.

Participants in the study will receive either pelacarsen or a placebo, which is a substance with no active medication, through an injection. The study will last for 52 weeks, during which the frequency of lipoprotein apheresis sessions will be monitored. The goal is to determine if pelacarsen can decrease the number of apheresis sessions needed by patients, potentially improving their quality of life and reducing the burden of treatment.

The trial is designed to compare the effects of pelacarsen with those of a placebo in a controlled setting. By the end of the study, researchers hope to demonstrate that pelacarsen is more effective than the placebo in reducing the rate of lipoprotein apheresis sessions in patients with hyperlipoproteinemia(a) and established cardiovascular disease. This could lead to new treatment options for managing this condition and its associated health risks.

The purpose of this study is to determine if lepodisiran is more effective than placebo in reducing cardiovascular events in people with high lipoprotein(a) levels. The study includes adults who either already have atherosclerotic cardiovascular disease or are at risk for having their first cardiovascular event. Cardiovascular events being monitored include death related to heart disease, myocardial infarction (heart attack), ischemic stroke (when blood flow to the brain is blocked), and urgent procedures to restore blood flow to the heart.

Participants in this study will be randomly assigned to receive either lepodisiran or placebo. The study will track how many participants experience cardiovascular events over time to determine if the medication is effective at reducing these outcomes compared to placebo.

The study will test inclisiran, given as an injection under the skin, against placebo while participants continue taking their usual cholesterol-lowering medications. These medications include either atorvastatin (40 mg daily) or rosuvastatin (20 mg or more daily), which belong to a group of drugs called statins that help lower cholesterol levels in the blood.

During the study, which will last for 72 months, participants will receive regular injections of either inclisiran or placebo along with their daily statin medication. The researchers will monitor participants to see if the combination of treatments helps prevent serious cardiovascular events like heart attacks and strokes.

The purpose of this study is to evaluate how well patients tolerate the treatment over an extended period. Participants will receive the treatment through injections under the skin, known as subcutaneous use. The study will monitor any adverse effects or serious adverse events, as well as changes in laboratory evaluations and vital signs. The study will also track the number of lipoprotein apheresis sessions, a procedure that removes certain fats from the blood, performed each year for up to five years.

Throughout the study, the levels of a specific type of fat in the blood, known as Lp(a), will be measured at various intervals to see how they change compared to the start of the previous study. This will help researchers understand the long-term impact of pelacarsen on cardiovascular health. Participants in this study have already completed a prior study and are considered safe to continue by their healthcare provider. The study aims to provide valuable information on the safety of pelacarsen for individuals with cardiovascular disease.

Participants in the study will receive either Obicetrapib or a placebo, which looks like the medication but does not contain the active ingredient. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo. This helps ensure the results are unbiased. The study will last for a period of time, during which participants will take the medication or placebo and attend regular check-ups to monitor their health and any changes in their condition.

The goal of the study is to gather information on how Obicetrapib affects the risk of serious cardiovascular events in people with ASCVD. By participating, researchers hope to better understand the potential benefits of this medication for those who are not adequately helped by their current treatments. The study will provide valuable insights into the effectiveness of Obicetrapib in managing heart and blood vessel health in individuals with this condition.

The medications being studied include INNOHEP (tinzaparin sodium), COUMADINE (warfarin sodium), Eliquis (apixaban), FRAGMINE (dalteparin sodium), Arixtra (fondaparinux sodium), SINTROM (acenocoumarol), HEPARINE CHOAY (heparin sodium), KARDEGIC (d,l-lysine acetylsalicylate), CALCIPARINE (heparin calcium), LOVENOX (enoxaparin sodium), Xarelto (rivaroxaban), and Plavix (clopidogrel). Some participants will receive a placebo, which is a substance with no active medication, to compare the effects of the actual treatments.

The purpose of the study is to determine if using full-dose anticoagulant therapy alone reduces the risk of significant bleeding compared to using it in combination with antiplatelet therapy. Participants will be monitored for up to 12 months to assess the occurrence of bleeding and other related health events. The study aims to provide insights into the safest and most effective treatment approach for patients with acute VTE who are also taking antiplatelet medications for other heart-related conditions.

The trial will compare the effects of Clazakizumab with a placebo, which is a substance that looks like the medication but does not contain the active ingredient. The study will also use a saline solution, which is a simple saltwater solution, as part of the trial process. The purpose of the study is to determine the best dose of Clazakizumab that can effectively reduce inflammation and to assess its safety in patients with ESKD. Participants will receive the medication or placebo through an intravenous injection, which means it is given directly into a vein.

Throughout the study, researchers will monitor the participants’ health and track any changes in their condition. The study will also look at the impact of Clazakizumab on cardiovascular health, which refers to the health of the heart and blood vessels. This is important because patients with ESKD are at a higher risk of developing heart-related issues. The trial is designed to provide valuable information on how Clazakizumab can help manage inflammation and improve overall health outcomes for patients with ESKD undergoing dialysis.

Participants in the study will receive either Olezarsen or a placebo through subcutaneous injection, which means the injection is given under the skin. The study will last for about 53 weeks, during which the changes in fasting triglyceride levels will be monitored. Fasting triglyceride levels refer to the amount of triglycerides in the blood after a period without eating. The study will also look at other health markers and events, such as changes in cholesterol levels and the occurrence of pancreatitis, which is inflammation of the pancreas, and major cardiovascular events like heart attacks or strokes.

The safety and tolerability of Olezarsen will be assessed by comparing it to the placebo. This includes monitoring for any adverse events, changes in vital signs, and results from physical exams and laboratory tests. The goal is to determine if Olezarsen is effective and safe for reducing triglyceride levels in patients with these conditions.

The purpose of the study is to determine if Inclisiran can reduce the risk of serious heart problems, such as heart attacks, strokes, or the need for urgent procedures to restore blood flow to the heart. The study will be conducted over a period of time, during which participants will receive regular injections of the medication or placebo and will be monitored for any heart-related events. The study is designed to be “double-blind,” meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo, to ensure unbiased results.

Participants will be closely observed throughout the study to track the time it takes for any major heart events to occur. The study will also look at other outcomes, such as the time to cardiovascular death and overall mortality. The goal is to gather information on the safety and effectiveness of Inclisiran in preventing heart-related issues in people who are at high risk but have not yet had a major cardiovascular event.